This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of -15.79% and 80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of 9.09% and 2.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 83.78% and 13.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of 37.50% and 2%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Verve Therapeutics (VERV) delivered earnings and revenue surprises of 13.24% and 12.77%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for VYNE Therapeutics Inc. (VYNE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Much Upside is Left in VYNE Therapeutics Inc. (VYNE)? Wall Street Analysts Think 626.2%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 626.2% in VYNE Therapeutics Inc. (VYNE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
OptiNose (OPTN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 118.18% and 14.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Can VYNE Therapeutics Inc. (VYNE) Climb 415.04% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for VYNE Therapeutics Inc. (VYNE) points to a 415% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
VYNE Gains on Preclinical Data for IPF Candidate
by Zacks Equity Research
VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0% and 67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About VYNE Therapeutics Inc. (VYNE) Rating Upgrade to Buy
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 13.33% and 58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 17.65% and 7.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About VYNE Therapeutics (VYNE) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to for VYNE Therapeutics (VYNE) stock based on the movements in the options market lately.
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of -5.88% and -12.51%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0.00% and -31.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 7.50% and -18.85%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 14.00% and -12.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?